CLEVELAND, Feb. 9 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it and PFC Pharma Focus, a CRO Connect Partner, will co-sponsor a seminar in Tel Aviv, Israel, focusing on eClinical solutions for the clinical trials industry. The topics addressed at the seminar will identify and decipher the challenges, costs and obstacles customarily encountered in implementing and integrating electronic data capture (EDC) and other eClinical solutions.
The seminar will take place at the Dan Hotel in Tel Aviv on Thursday, March 4, 2010. Speakers include Tamar Yardeni-Nadiv, Director, Head of Global Data Management at Teva Pharmaceuticals Industries, Ltd; Tali Azulay, Senior Consultant at BioForum's Clinical Data Management Center; Ran Frenkel, Chief Executive Officer at Pharma Focus Israel; and Bill Coates, Vice President Global Marketing and Sales at DATATRAK International.
To register for this seminar, please contact PFC Pharma Focus Israel at +972-3-5360623 or register online at http://www.regonline.com/Checkin.asp?EventId=821799. You can also find additional information on the seminar at DATATRAK's website; please visit http://www.datatrak.net/2010/02/05/upcoming-events-for-datatrak-in-march/.
About PFC Pharma Focus.
Based in Switzerland, Germany, India and Israel, PFC Pharma Focus is a premium contract research organization (CRO), providing product development services in the life science and health care industries. Founded in 1992 by prominent experts in all realms of clinical services, the mission of PFC Pharma Focus is to bring a new look to the drug development experience by addressing the limitations of conventional study practices. This year marks PFC Pharma Focus's 18th anniversary providing clinical services, and our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. PFC Pharma Focus's services encompass clinical development consultancy, clinical operations and project management, medical writing, regulatory affairs, training in pharmaceutical medicine and development of risk management plans. For more information visit: http://www.pfc-cro.com.
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE™, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical™ product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.
|SOURCE DATATRAK International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved